Chemotherapy drug outperforms remdesivir against SARS-CoV-2 in lab experiments: Study

PTI, Jan 3, 2021, 3:15 PM IST

Beijing: A chemotherapy medication originally developed to treat cancer could potentially be repurposed to inhibit the replication of the novel coronavirus and treat COVID-19, according to a study based on computer simulations and lab experiments.

The research, published in the journal PLOS Computational Biology, combined multiple computational techniques that simulate drug-virus interactions from different, complementary perspectives.

Using this hybrid approach, scientists from the Shenzhen Institutes of Advanced Technology in China, screened 1,906 existing drugs for their potential ability to inhibit replication of the novel coronavirus by targeting a viral protein called RNA-dependent RNA polymerase (RdRP).

The researchers identified four promising drugs, which were then tested against the SARS-CoV-2 virus in lab experiments.

They said two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus, and further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir – a drug that is currently used to treat some COVID-19 patients.

According to the scientists, the findings suggest that pralatrexate could potentially be repurposed to treat COVID-19.

However, the researchers said the chemotherapy drug may prompt significant side effects and is used for people with terminal lymphoma, so they added that immediate use for COVID-19 patients is not guaranteed.

But the research highlighted the importance of the new screening strategy to identify drugs that could be repurposed.

”We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics,” said study author Haiping Zhang of the Shenzhen Institutes of Advanced Technology.

The researchers are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat COVID-19.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Have done no wrong, only did party work, says K’taka deputy CM Shivakumar facing DA case

K’taka HC allows D K Shivakumar to file memo seeking withdrawal of his appeal in DA case

Couple’s argument leads to diversion of Lufthansa flight at IGI

K’taka to unveil revised biotech policy: CM at Bengaluru Tech Summit

Rahul Gandhi shares humorous campaign tale on translation troubles

Crayon Software Experts India launches its first ISV Incubation Center in India with AWS

Feticide case: Administrative system failure exposed, says HDK

Related Articles More

Amazon launches ‘Q’, a business chatbot powered by generative artificial intelligence

ISRO’s AstroSat detects over 600 gamma-ray bursts over 8 years

Google will start deleting ‘inactive’ accounts in December. Here’s what you need to know

Court document claims Meta knowingly designed its platforms to hook kids, reports say

Prehistoric women engaged in hunting, their anatomy suitable for it: US researchers


Halalban by Uttarapradesh government

Unnakki utsava Mudigere

Singer Gurukiran speaking about Kambala

Bangalore kambala preparations

Skin Care |Chithrakoota Ayurveda

Latest Additions

Amit Shah accuses TMC MPs of bringing disgrace to Parliament

Playing under great leaders will help me a lot in this IPL: Gill on Gujarat Titans captaincy

Have done no wrong, only did party work, says K’taka deputy CM Shivakumar facing DA case

Govt approves terms of reference for 16th Finance Commission

Cabinet nod for Rs 1,261 cr scheme to provide drones to 15,000 women SHGs for 2 years

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.